tirzepatide abbreviation The promise of tirzepatide: A narrative review of metabolic benefits 🧠Let's break the drug tirzepatide

Individual responses vary significantly, and not all patients experience measurable anti-inflammatory benefits

It does not cause dependence, does not interact with GLP-1 receptor agonists, and works through an osmotic mechanism rather than stimulating the colon directly

However, they can still impact the endocrine system, insulin sensitivity, and IGF-1 axis with prolonged or high-dose use

Mechanism of Action: The Unbound Agonist

The Achieve-3 trial, funded by Eli Lilly, studied more than 1,500 adults with type 2 diabetes from 131 medical research centres and hospitals in Argentina, China, Japan, Mexico and the US